Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$412K Buy
1,137
+1
+0.1% +$342 0.06% 127
2026
Q1
$400K Sell
1,136
-2
-0.2% -$713 0.07% 127
2025
Q4
$373K Sell
1,138
-61
-5% -$19.4K 0.07% 130
2025
Q3
$338K Sell
1,199
-40
-3% -$11.6K 0.06% 134
2025
Q2
$346K Buy
1,239
+414
+50% +$117K 0.07% 125
2025
Q1
$257K Hold
825
0.06% 145
2024
Q4
$215K Hold
825
0.05% 160
2024
Q3
$266K Buy
825
+1
+0.1% +$327 0.05% 143
2024
Q2
$258K Buy
824
+75
+10% +$22K 0.06% 142
2024
Q1
$213K Sell
749
-99
-12% -$29K 0.05% 144
2023
Q4
$244K Hold
848
0.06% 138
2023
Q3
$228K Buy
+848
New +$212K 0.06% 146
2023
Q2
Sell
-846
Closed -$222K 150
2023
Q1
$222K Hold
846
0.07% 144
2022
Q4
$222K Buy
+846
New +$227K 0.07% 144
2022
Q3
Sell
-845
Closed -$206K 146
2022
Q2
$206K Hold
845
0.06% 148
2022
Q1
$204K Buy
+845
New +$194K 0.06% 160

Other funds holding AMGN

Essex LLC's AMGN Position: Q2 2026 in Review

Essex LLC increased its Amgen (AMGN) stake by 0.09% in Q2 2026, buying an estimated $342 and bringing the position to 1,137 shares worth $412K. The position accounts for 0.06% of the portfolio, ranked #127.

Essex LLC first reported a position in AMGN in Q1 2022 and has held it in 16 quarters since. 1,447 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Essex LLC held 1,137 shares of Amgen worth $412K as of Q2 2026.
  • Essex LLC bought 1 Amgen share in Q2 2026, an estimated $342.
  • Amgen made up 0.06% of Essex LLC's portfolio in Q2 2026, its #127 holding.
  • Essex LLC first reported a position in Amgen in Q1 2022 and has held it in 16 quarters since.
  • 1,447 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Essex LLC's 13F filing for Q2 2026, filed 24 Jul 2026.